These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35589649)

  • 1. [Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge].
    Sakata M; Ito H
    Brain Nerve; 2022 May; 74(5):571-574. PubMed ID: 35589649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Treatments for Tardive Dyskinesia].
    Nomoto M
    Brain Nerve; 2022 May; 74(5):565-570. PubMed ID: 35589648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tardive dyskinesia].
    Zalyalova ZA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7):25-31. PubMed ID: 37490662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
    Meyer JM
    CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    Khurram SK; Ames M; Muniz J
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):220-221. PubMed ID: 33587391
    [No Abstract]   [Full Text] [Related]  

  • 9. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 11. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Tardive Syndrome: Medications and Surgical Treatments.
    Factor SA
    Neurotherapeutics; 2020 Oct; 17(4):1694-1712. PubMed ID: 32720245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valbenazine for the treatment of tardive dyskinesia.
    Müller T
    Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.